Endocrine System Diseases  >>  BIAsp 30 (biphasic insulin aspart 30/70 biosimilar)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

14 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BIAsp 30 (biphasic insulin aspart 30/70 biosimilar) / Novo Nordisk
NCT01620424: Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes

Completed
1
10
Japan
biphasic insulin aspart 30, biphasic insulin aspart 50
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
04/01
04/01
NCT01524809: Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes

Completed
1
26
Europe
biphasic insulin aspart 30, biphasic insulin aspart 70
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
06/01
06/01
NCT01526941: Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes

Completed
1
27
Europe
biphasic insulin aspart 30, biphasic insulin aspart 70
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
07/01
07/01
NCT01536028: Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes

Completed
1
32
Europe
biphasic insulin aspart 30, biphasic insulin aspart 50, biphasic insulin aspart 70, insulin aspart
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
07/06
07/06
NCT01865305: Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes

Completed
1
59
Europe
insulin degludec/insulin aspart 30, insulin degludec/insulin aspart 40, insulin degludec/insulin aspart 50, insulin degludec, insulin aspart, biphasic insulin aspart 30
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
02/07
02/07
NCT01538511: Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers

Completed
1
59
Japan
biphasic insulin aspart 70, biphasic insulin aspart 30
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
03/07
03/07
NCT00825253: Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes

Completed
1
24
Europe
biphasic insulin aspart 30, biphasic human insulin 30
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
05/07
05/07
NCT00824668: Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes

Completed
1
24
Europe
biphasic insulin aspart 30, insulin glargine, insulin glulisine
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
10/07
10/07
NCT01868568: Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes

Completed
1
55
Europe
insulin degludec, insulin degludec/insulin aspart 30, insulin degludec/insulin aspart 40, insulin degludec/insulin aspart 45, insulin degludec/insulin aspart 55, insulin aspart, biphasic insulin aspart 30, placebo
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
08/08
08/08
NCT00993096: Investigation of the Response Relationship of NN5401 in Type 1 Diabetics

Checkmark EASD 2013
Jul 2013 - Jul 2013: EASD 2013
Completed
1
33
Europe
insulin degludec/insulin aspart, biphasic insulin aspart 30
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
12/09
12/09
NCT01051102: Effect of NN5401 in Japanese Subjects With Type 1 Diabetes

Completed
1
21
Japan
insulin degludec/insulin aspart, biphasic insulin aspart 30
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
04/10
04/10
NCT01134224: A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes

Completed
1
39
Europe
insulin degludec/insulin aspart, biphasic insulin aspart 30
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
11/10
11/10
NCT01174303: A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes

Completed
1
28
Europe
insulin degludec/insulin aspart, biphasic insulin aspart 30
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
11/10
11/10
CORRECT, NCT02587741: Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens

Recruiting
1
600
RoW
Metformin, gliclazide modified release tablets, acarbose, Lantus, Novomix30
Third Affiliated Hospital, Sun Yat-Sen University
Diabetic Retinopathy
07/23
07/25

Download Options